IBDEI391 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,54602,1,3,0)
 ;;=3^Malig Neop of Thyroid Gland
 ;;^UTILITY(U,$J,358.3,54602,1,4,0)
 ;;=4^C73.
 ;;^UTILITY(U,$J,358.3,54602,2)
 ;;=^267296
 ;;^UTILITY(U,$J,358.3,54603,0)
 ;;=E10.21^^256^2767^8
 ;;^UTILITY(U,$J,358.3,54603,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54603,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,54603,1,4,0)
 ;;=4^E10.21
 ;;^UTILITY(U,$J,358.3,54603,2)
 ;;=^5002589
 ;;^UTILITY(U,$J,358.3,54604,0)
 ;;=E10.9^^256^2767^12
 ;;^UTILITY(U,$J,358.3,54604,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54604,1,3,0)
 ;;=3^DM Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,54604,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,54604,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,54605,0)
 ;;=E11.21^^256^2767^17
 ;;^UTILITY(U,$J,358.3,54605,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54605,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,54605,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,54605,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,54606,0)
 ;;=E11.39^^256^2767^18
 ;;^UTILITY(U,$J,358.3,54606,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54606,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Ophthalmic Complication NEC
 ;;^UTILITY(U,$J,358.3,54606,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,54606,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,54607,0)
 ;;=E11.43^^256^2767^15
 ;;^UTILITY(U,$J,358.3,54607,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54607,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Autonomic Neuropathy
 ;;^UTILITY(U,$J,358.3,54607,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,54607,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,54608,0)
 ;;=E11.59^^256^2767^13
 ;;^UTILITY(U,$J,358.3,54608,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54608,1,3,0)
 ;;=3^DM Type 2 w/ Circulatory Complications NEC
 ;;^UTILITY(U,$J,358.3,54608,1,4,0)
 ;;=4^E11.59
 ;;^UTILITY(U,$J,358.3,54608,2)
 ;;=^5002652
 ;;^UTILITY(U,$J,358.3,54609,0)
 ;;=E11.618^^256^2767^14
 ;;^UTILITY(U,$J,358.3,54609,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54609,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Arthropathy NEC
 ;;^UTILITY(U,$J,358.3,54609,1,4,0)
 ;;=4^E11.618
 ;;^UTILITY(U,$J,358.3,54609,2)
 ;;=^5002654
 ;;^UTILITY(U,$J,358.3,54610,0)
 ;;=E11.621^^256^2767^16
 ;;^UTILITY(U,$J,358.3,54610,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54610,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,54610,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,54610,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,54611,0)
 ;;=E11.622^^256^2767^20
 ;;^UTILITY(U,$J,358.3,54611,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54611,1,3,0)
 ;;=3^DM Type 2 w/ Skin Ulcer NEC
 ;;^UTILITY(U,$J,358.3,54611,1,4,0)
 ;;=4^E11.622
 ;;^UTILITY(U,$J,358.3,54611,2)
 ;;=^5002657
 ;;^UTILITY(U,$J,358.3,54612,0)
 ;;=E11.65^^256^2767^19
 ;;^UTILITY(U,$J,358.3,54612,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54612,1,3,0)
 ;;=3^DM Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,54612,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,54612,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,54613,0)
 ;;=E11.9^^256^2767^21
 ;;^UTILITY(U,$J,358.3,54613,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54613,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,54613,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,54613,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,54614,0)
 ;;=E13.9^^256^2767^22
 ;;^UTILITY(U,$J,358.3,54614,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54614,1,3,0)
 ;;=3^Diabetes Mellitus (Secondary) w/o Complications NEC
 ;;^UTILITY(U,$J,358.3,54614,1,4,0)
 ;;=4^E13.9
 ;;^UTILITY(U,$J,358.3,54614,2)
 ;;=^5002704
 ;;^UTILITY(U,$J,358.3,54615,0)
 ;;=E16.2^^256^2767^29
